EC approves Eylea for wet AMD

The European Commission approved an MAA from Bayer AG (Xetra:BAYN) for Eylea aflibercept to treat wet age-related macular degeneration (AMD). The product is approved in the U.S for the indication and for macular edema following central retinal vein occlusion (CRVO). Bayer said it plans to submit a regulatory application in Europe by year end to expand Eylea's label to include treatment of macular edema following CRVO. ...